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INTRODUCTION 
 
Renal failure is a major challenging complication in patients with 
chronic liver disease patients and is one of the most important risk factor 
associated with mortality and liver transplantation is considered.  
 
Patients  with  cirrhosis  are susceptible to develop  renal failure  due to 
persistent vasodilatory state, reduced effective blood volume and stimulation 
of vasoconstrictor hormones.  
 
Infection is a major risk factor precipitating renal failure in liver disease 
 
Renal parameters should be monitored routinely in all patients with 
cirrhosis due to potiential risk of renal failure during hospitalisation 
 
Patients with cirrhosis and renal failure are at higher risk for death 
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AIM OF THE STUDY 
 
 
1. To identify the precipitating /risk factors associated with the renal 
failure in patients with chronic liver disease  
 
2. To study the  clinical profile in patients with cirrhosis who developed 
the renal failure 
 
3. To assess the outcome of renal failure on mortality in a period of  two 
weeks of follow up ( in hospital mortality) 
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REVIEW OF LITERATURE 
 
HISTORY 
• Frerichs and Flint made first description of disturbances in renal 
function in chronic liver disease from the late nineteenth century. They 
were the first to discuss about the development of oliguria in chronic 
liver disease patients in the absence of proteinuria and with a normal 
renal histology. They proposed the first pathophysiologic  interpretation 
of hepatorenal syndrome by linking the abnormalities of renal function 
to the disturbances present in systemic circulation. 
 
• Term “ Hepato renal syndrome” was coined by Helwig and Schutz in 
1932. However, studies by Sherlock,PapperandVessin in 1950s gave 
detailed description of HRS. 
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PATHOPHYSIOLOGY OF RENAL DYSFUNCTION IN LIVER 
DISEASE 
 
• Interaction between changes in the systemic arterial circulation, portal 
hypertension, activation of vasoconstrictors and suppression of 
vasodilatory factors acting on the renal circulation is the basis for the 
development of renal dysfunction in advanced liver disease. 
 
• Pre-renal failure frequently occurs in patients with advanced liver disease 
due to disturbances in circulatory function-mainly portal hypertension 
induced primary arterial vasodilation in the splanchnic circulation leading 
to decreased systemic vascular resistance. Increased production of 
vasodilator factors like nitric oxide,carbon monoxide and  cannabinoids 
leads to further arterial vasodilation. 
 
• True hypovolemia induced by gastrointestinal tract hemorrhage from 
varices,peptic ulcers or gastropathy,excessive diuresis, GI loses in the 
form of vomiting and diarrhea ,large volume paracentesis without 
intravascular volume replacement further worsens renal dysfunction. 
NSAIDs and bacterial infections also worsens pre-renal failure in these 
patients. 
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PATHOPHYSIOLOGY OF BOTH COMPENSATED AND DECOMPENSATED 
CIRRHOSIS 
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SODIUM RETENTION AND ASCITES 
 
• This is considered as the first manifestation of renal dysfunction in 
cirrhosis. Amount of sodium retained depends on the balance  between 
sodium intake and excretion. Ascites develops when sodium intake is 
increased or when treated with drugs which increase sodium 
reabsorption like NSAIDs or mineralocorticoids. 
 
• Increased renal tubular reabsorption of sodium in the proximal and 
distal tubules is the basis for renal sodium retention. This can occur 
even with normal or only moderately reduced GFR.  
 
• Renin-angiotensin-aldosterone system and sympathetic nervous system 
are the two main sodium retaining systems which are activated as a 
homeostatic response to circulatory dysfunction 
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DILUTIONAL HYPONATREMIA 
 
• Excessive retention of solute free water due to decreased excretion by 
kidneys results in hyponatremia in patients with cirrhosis and ascites.  
 
• Solute free water retention in cirrhosis is due to decreased delivery of 
filtrate to the ascending limb of loop of Henle,reduced renal synthesis 
of prostaglandins and increased secretion of anti-diuretic hormone. 
 
• Central nervous system disturbances are the cause for morbidity and 
mortality associated with hyponatremia. Steroid and peptide hormone 
changes in cirrhotic patients leads to hyponatremia induced 
encephalopathy which often overlaps with hepatic encephalopathy and 
uremia. Development of hyponatremia in cirrhotic patients can be 
considered as a marker of unrecognized underlying renal dysfunction. 
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RENAL VASOCONSTRICTION 
 
Decreased renal perfusion as a result of renal vasoconstriction develops 
last in patients with cirrhosis and ascites. Marked vasodilation of splanchnic 
circulation leads to extreme underfilling of the systemic arterial circulation 
which results in activation of homeostatic vasoconstrictor system.This cannot 
be counteracted by either renal or systemic vasodilators. Renal 
vasoconstriction leads to the development of hepatorenal syndrome 
 
 
TYPES OF RENAL FAILURE IN PATIENTS WITH CIRRHOSIS 
 
 
A. HYPOVOLEMIA INDUCED RENAL FAILURE 
 
Gastrointestinal hemorrhage, excessive diuretic use,prolonged 
diarrhea due to excessive lactulose administration  leads to 
hypovolemia which then leads to renal failure. 
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B. PARENCHYMAL RENAL DISEASE 
When proteinuria(more than 500 mg of protein/day), hematuria more 
than 50 red cells/hpf) or both are present, parenchymal renal disease 
should be considered as a cause of renal failure which can be confirmed 
by renal biopsy, if not contraindicated. Renal tubular epithelial cells in 
urine sediment supports the diagnosis of acute tubular necrosis. 
 
C. DRUG INDUCED RENAL FAILURE 
Nonsteroidal anti-inflammatory drugs or aminoglycosides  use suggests drug 
induced renal failure. 
 
D.HEPATORENAL SYNDROME 
HRS is regarded as the ultimate stage of pathophysiologic condition 
characterized by decreased renal blood flow as a result of 
decompensated liver function in patients with cirrhosis and ascites. It is 
a type of functional renal failure which develops as a complication of 
advanced liver disease,liver failure or portal hypertension. It is a result 
of severe constriction of renal arterial vasculature with resulting 
oliguria and sodium retention. Hemodynamic changes associated with 
10 
 
endothelial shear stress occur before the onset of ascites which are 
sustained by an increase in pro angiogenic factors like VEGF, PDGF 
and vasodilators like carbon monoxide, endocannabinoids and nitric 
oxide which are able to promote the formation of hepatic, splanchnic 
and portosystemic collateral vessels. HRS can occur spontaneously or 
as a result of infection, gastrointestinal bleeding and post-paracentesis 
circulatory dysfunction. 
 
              The renal impairment is further worsened by progressive 
cardiac dysfunction (cirrhotic cardiomyopathy). Its characteristic 
features include diastolic impairment with septal ventricular 
hypertrophy, blunted ventricular response to stress, systolic and 
diastolic dysfunction and electrophysiological abnormalities (prolonged 
QT interval). Systolic dysfunction results from impaired β-adrenergic 
receptor and increased endogenous cannabinoids and 
cardiosuppressants like nitric oxide, inflammatory cytokines and 
myocyte apoptosis. 
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            Diastolic dysfunction results from activation of renin-angiotensin 
system and salt retention. Myocardial dysfunction in cirrhosis is regarded as 
a precipitating factor for HRS. 
 
 There are two forms of hepatorenal syndrome  
 
TYPE I HRS 
It is a form of AKI. It is characterized by acute onset and rapidly 
progressing kidney failure with a doubling of serum creatinine to more than 
2.5 mg/dl (corresponding to a 50% reduction in the creatinine clearance rate) 
in less than 2 weeks, usually associated with multi organ damage. The 
prognosis is poor with only 10% of patients surviving longer than 90 days. 
 
       This type of hepatorenal syndrome can either develop spontaneously or 
due to precipitating factors.The precipitating factors / events are mostly due to 
gastrointestinal bleeding, spontaneous bacterial peritonitis, infections like 
pneumonia, cellulitis, urinary tract infections. Other potiential risk events are 
viral, alcoholic or ischemic hepatitis like TIPS(transjugular intrahepatic 
portosystemic shunt) and include surgical procedures 
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TYPE II HRS 
 
      It is a form of CKD. It represents the final kidney response to 
hemodynamic impairments in cirrhosis.This type of renal failure is more 
gradual in onset and associated with diuretic resistant refractory 
ascites.Most often patients will have gross ascites.It is less severe form 
compared to type1 HRS. The increase in creatinine is gradual with mean 
values of around 1.5-2.0 mg/dl.Type 2 HRS can precipitate Type 1 HRS 
either with or with out precipitating event. Patients after developing HRS 
type 2 can survive upto 6- 8 months duration depends on the various 
factors. 
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CHARACTERISTICS OF TYPE I AND TYPE II HEPATORENAL 
SYNDROME 
 
HRS I  HRS II 
Doubling of serum creatinine 
in<2 wk 
 
 
Renal impairment gradually 
progressive 
A precipitating event is present 
in most of the cases 
 
 
No precipitating event 
No history of diuretic resistant 
ascites 
 
 
Always diuretic resistant ascites 
10% survival in 90 days without 
treatment 
 
 
Median survival is  6 months 
 
 
  The differential diagnosis between these two types of HRS is based on 
the rate of progression and extent of renal impairment. Spontaneous recovery 
is rare in both types. 
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      The AKI network(AKIN) has proposed a newer definition of AKI 
for the diagnosis of HRS for prompt recognition of kidney damage. 
AKI is defined as the abrupt loss of kidney function resulting in a 0.3 
mg/dl increase in serum creatinine in 48 h or a 50% increase over the 
basal value. Recent studies have shown that AKI with serum creatinine 
values <1.5 mg/dl is a relatively benign and potentially reversible 
condition, whereas the progression of renal deterioration to a 
significant decrease in GFR (values >1.5 mg/dl) carries a poor 
prognosis. 
        With the onset of AKI in patients with cirrhosis, we have to 
differentiate from other forms of kidney injury: Pre-renal (45%), Acute 
tubular necrosis and Glomerulonephritis(32%) and Obstructive 
nephropathy(<1%). The traditional parameters used to differentiate 
AKI from CKD (urinary sodium concentration, serum and urine 
osmolarity) cannot be used in patients with cirrhosis and ascites. 
Impaired hepatic synthesis leads to reduced synthesis of urea.  Raised 
urinary levels of neutrophil gelatinase associated lipocalin (NGAL) 
helps to differentiate functional kidney damage from acute tubular 
necrosis or necrosis due to HRS. 
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PATHOGENESIS OF HEPATORENAL SYNDROME 
       HRS can lead to gross reduction in GFR with less renal histologic 
abnormalities which is a consequence of functional renal vasoconstriction. 
Correction of portal hypertension by liver transplantation leads to restoration 
of renal function. 
 
      Primary abnormality in HRS is peripheral and splanchnic arterial 
vasodilation due to portal hypertension. Ensuing vasoconstriction and renal 
sodium and water retention are adaptive responses to vasodilation. 
 
Mechanisms contributing to pathogenesis of HRS : 
 
1. Renin-Angiotensin-Aldosterone system (RAAS) 
Most cirrhotic patients with ascites and marked sodium retention 
have elevated plasma aldosterone levels which is caused by 
stimulation of aldosterone secretion and not due to impaired 
degradation.  
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Increased tubular sensitivity to aldosterone is seen in patients with 
cirrhosis which explains the renal sodium retention even with 
normal levels of aldosterone. Hence, aldosterone antagonistic drugs 
like spironolactone helps to reverse sodium retention and causes 
natriuresis in cirrhotic patients. 
 
 Patients with decompensated cirrhosis have elevated plasma renin 
activity. Administration of vasopressin analogues like terlipressin 
improves renal function in patients with HRS by causing marked 
suppression of RAAS activity. 
 
2. Sympathetic nervous system  
       Higher plasma norepinephrine levels are seen in patients with 
hepatorenal syndrome than those without renal failure. This has 
inverse correlation with renal blood flow which suggests the role of 
sympathetic nervous system in causing renal vasoconstriction seen 
in patients with HRS. 
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        Patients with HRS are also found to have elevated circulating 
levels of Neuropeptide Y, a neurotransmitter with potent 
vasoconstrictor action in the renal circulation released when there is 
activation of sympathetic nervous system. Its levels are not elevated 
in those with ascites without renal failure. 
 
3. Prostaglandins: 
        Lower urinary excretion of PGE2 and PGI2 is seen in patients 
with hepatorenal syndrome than do patients with ascites and without 
renal failure. This hints at the fact that decreased renal synthesis of 
vasodilator prostaglandins might play a role in the pathogenesis of 
HRS. Arterial vasodilation in cirrhosis can be attributed to increased 
systemic prostaglandin synthesis, which are potent vasodilators in 
the systemic circulation. 
 
Non steroidal anti-inflammatory drugs decrease GFR and renal 
plasma flow which shows prostaglandins have a role in maintaining 
normal renal perfusion. 
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          Irreversible vasoconstriction seen in HRS can be attributed to 
an imbalance between vasodilator and vasoconstrictor metabolites 
of arachidonic acid, with the latter dominating. 
 
4. Adenosine: 
Intrahepatic adenosine triggers hepatorenal reflex by causing 
an increase in portal venous blood flow which increases sympathetic 
activity in the kidney leading to a decrease in renal blood flow and 
GFR, leading on to hepatorenal syndrome. Advanced liver 
dysfunction induced  tissue hypoxia leads to increased synthesis of 
adenosine. 
 
5.  Nitric oxide(NO) : 
Nitric oxide released from vascular smooth muscle is a 
powerful vasodilator agent. It causes splanchnic vasodilation in 
cirrhosis. It modulates arteriolar tone and the contractility of 
mesangial cells thereby regulating glomerular microcirculation. It is 
involved in the regulation of renin release and facilitates natriuresis.   
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        With the progression of liver disease, level of nitric oxide 
increases significantly which indicates that NO is essential for the 
progression of cirrhosis. 
 
6. Endothelin: 
        Endothelin-1 is  an endothelial derived peptide with  potent 
vasoconstrictor effect whose levels are increased in cirrhosis as a 
result of increased release of the peptide from the hepatic and 
splanchnic circulation. Excessive intrarenal production and 
increased circulating levels of endothelin may lead to renal 
vasoconstriction and cause hepatorenal syndrome. 
 
7. Natriureticpeptides:                                                                                                       
 In patients with cirrhosis and ascites, plasma                                                    
concentration of atrial natriuretic peptide and brain natriuretic 
peptide are elevated. Increased cardiac release is responsible for it 
and it is not a result of decreased hepatic or systemic clearance.  
 
20 
 
 
They have strong effect on renal function( vasodilator and 
natriuretic effects) and inhibits renin release. Thereby, they counteract the 
effects of anti-natriuretic and vasoconstrictor systems in renal circulation. 
Coexistence of elevated plasma levels of ANP in cirrhosis in the presence of 
renal sodium retention signals renal resistance to the effects of ANP. 
 
 
8. Endotoxins: 
        Because of patient’s immunosuppressed status in cirrhosis, entire 
gastrointestinal tract becomes densely colonized with bacteria. Jaundice in 
cirrhosis promotes reabsorption of endotoxin into the bloodstream. 
Absorbed endotoxin would appear in the arterial circulation due to 
incomplete destruction by hepatic Kupffer cells which in turn is due to 
compromised function of reticuloendothelial cells of the liver in advanced 
cirrhosis. Vasoconstriction of renal microcirculation is the end result of 
continuous reabsorption of endotoxin from gastrointestinal tract into the 
circulation of cirrhotic patients. 
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         To conclude, the fluid retention and hepatorenal syndrome is 
attributed to the peripheral vasodilation which is the early event in 
the pathogenesis. The maintenance of normal renal perfusion 
depends on the balance between vasodilatory and vasoconstricting 
factors following initial vasodilation. There is a preponderance of 
vasoconstriction over vasodilation in hepatorenal syndrome which 
leads to increased renal vascular resistance, decrease in GFR and 
avid sodium and water retention. 
 
 
NEWER DIAGNOSTIC CRITERIA FOR HEPATORENAL 
SYNDROME 
Cirrhosis and ascites 
Serum Creatinine more than 1.5 mg/dl 
No shock 
No improvement in serum creatinine(decrease to a level of 1.5mg/dl or less) 
after at least 2 days of diuretic withdrawl and volume expansion with 
albumin(The recommended dose of albumin is 1g/kg of body weight per day 
up to a maximum of 100g/day) 
No current or recent exposure to nephrotoxic drugs 
Absence of parenchymal disease as indicated by proteinuria more than 500 
mg/d, microscopic hematuria(i.e, 50 red blood cells in high power field) and 
abnormal renal ultrasonography 
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PREVENTION AND SUPPORTIVE CARE 
The cirrhotic patient with ascites must be closely monitored to avoid 
precipitating factors and treat them. The aim of treatment must be to 
stabilize patients until liver transplantation and optimize their clinical 
condition for a successful transplant. 
 
 
PREVENTION OF HEPATORENAL SYNDROME AND GENERAL 
PATIENT MANAGEMENT STRATEGIES 
Avoid drugs that reduce renal perfusion or nephrotoxic substances 
Minimize exposure to organ-iodated contrast agents 
Intravenous albumin is recommended for volemic filling after large volume 
paracentesis(8 g of albumin for each litre of ascites removed) 
Diuretic therapy should be suspended  
Pentoxifylline as drug’s anti-TNF alpha activity 
Antibiotic prophylaxis to prevent infections reducing intestinal bacterial 
translocation(norfloxacin 400mg/d) 
Intravenous albumin administered in association with ceftrixone in SBP 
Adrenal insufficiency should be identified and treated 
Drug dosages must be adjusted according to renal function 
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TREATMENT OF HEPATORENAL SYNDROME 
 
Currently available treatments enhance patient’s short term survival but 
offer little benefit in the longer term. Liver transplant remains the only truly 
effective treatment but is limited by the high mortality rate in  HRS patients 
and the shortage of available organs. Pre-transplant kidney function is the 
most important predictor for patient survival after liver transplant. 
Pharmacological treatment and medical care serve as a “bridge” to transplant 
to improve the patient’s prognosis. 
 
Medical management 
• Ideal treatment is to exert splanchnic vasoconstriction and renal 
vasodilation to reduce portal hypertension and raise systemic 
arterial pressure. 
• Vasoconstrictor agents (terlipressin,norepinephrine,midodrine) 
are used to correct circulatory changes. 
• Intravenous administration of terlipressin and albumin is 
currently the treatment of choice for patients with type I and type 
II HRS, resulting in an overall reduction in short term mortality 
rates.  
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• The vasocontrictive effect of terlipressin corrects the circulatory 
dysfunction typical of end stage liver disease, indirectly 
rebalancing intrarenal vasoconstriction and lowering levels of 
renin, noradrenaline and ultimately serum creatinine. 
Also,terlipressin increases hepatic arterial blood flow and 
improves hepatocellular oxygenation. 
 
• Terlipressin can be administered as an intravenous bolus starting 
from a dose of 0.5mg every 4-6 h or as a continuous infusion 
(2mg/d). Total daily dose should not exceed 2mg IV bolus every 
4-6 h or 12 mg/d in continuous infusion. 
 
• Terlipressin should be combined with albumin (at a dose of 1g/d 
on the first day, without exceeding 100g/d, followed by 20-
40g/d). It raises oncotic pressure and expands circulating 
volume. In addition, it has metabolic, immune and 
vasoconstrictor effects by binding to endotoxins, nitric oxide, 
bilirubin and fatty acids. The terlipressin-albumin association 
improves renal function by 40-60%. Treatment is completed 
when serum creatinine values reach <1.5 mg/dl. 
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• The alpha-adrenergic receptor agonist norepinephrine is effective 
in the treatment of HRS. Continuous norepinephrine infusion (at 
a dose of 0.5-3 mg/h) must be associated with albumin 
administered as an IV bolus at least twice daily (1g/kg up to a 
maximum of 100g/d). Aim is to raise mean arterial pressure by 
10 mmHg and urinary output >200 mL every four hours. The 
maximum period of treatment must not exceed 2 weeks 
 
 
• Midodrine is an alternative to terlipressin. It is a prodrug which 
is metabolized by the liver and then excreted through urine. 
 
• If the midodrine is given along with octreotide , it has favourable 
effect on renal failure. Possibility of even 50% improvement is 
there. It is administered orally 7.5 mg every 8 hrly maximum 
upto 12.5 mg thrice a day. Albumin must be used as routine 
dosage.  
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TIPS  - It can be used as short term procedure to gain benefits from 
awaiting liver transplant patients. High incidence of hepatic 
encephalopathy is major side effect of this procedure. 
 
Renal replacement therapy 
It is indicated in patients with severe renal failure with complications 
like metabolic acidosis, hyperkalemia etc.. It is used as bridging therapy in 
liver transplant patients. No evidence proved that dialysis will improve the 
long term survival rate. Continous renal replacement is better than 
intermittent dialysis in view of hemodynamic fluctuations. Peritoneal dialysis 
is option to resolve the ascites and correct other complications with exposing 
the patient to hemodialysis 
 
The molecular adsorbent recirculating system (MARS) has been used 
in the treatment of acute decompensation of chronic liver disease, acute liver 
failure and hepatorenal syndrome.This liver support system utilizes either 
intermittent (6-8 h daily) or continuous hemodialysis with dialysate enriched 
with 20% human serum albumin as a means to remove  albumin-bound  
toxins  (bilirubin,  bile  acids,  fatty  acids, tryptophan, aromatic amino acids, 
and copper) 
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Liver transplantation- It is the definitive treatment of hepatorenal syndrome 
for both types. Recovery of renal function is not universal. MELD score is 
used for organ transplantation.RRT prior to liver transplant has poor 
prognosis. This patients may require combined liver-kidney transplant. 
 
 Causes of Renal Failure in Patients With Cirrhosis 
• Infections 
• UGI Bleeding (with / without shock) 
• Spontaneous bacterial peritonitis  
• Spontaneous bacteremia 
• Urinary tract infection 
• Pneumonia 
• skin infection ( celluluitis), other bacterial infections 
• Hypovolemia-induced renal dysfunction  
• Diuretic-induced  
• Acute  gastro enteritis 
• Hepatorenal syndrome 
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Intrinsic renal diseases  
 
Glomerulopathy:  
Membranous nephropathy, membranoproliferative glomerulonephritis, 
polyarteritis nodosa, or cryoglobulinemia due to viral hepatitis, Chronic 
kidney disease due to diabetes, hypertension, or other causes  
 
Drug-induced renal failure  
Hemodynamically induced: non steroidal anti-inflammatory agents or 
angiotensin receptor blockers  
 
Acute tubular necrosis: aminoglycosides, amphotericin B, or tenofovir 
 
Acute interstitial nephritis: penicillin, rifampacin, or sulfonamides 
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EVALUATION OF PATIENTS WITH CIRRHOSIS AND RENAL 
FAILURE 
 
 Renal function should be routinely monitored in all patients with 
advanced cirrhosis, especially in patients those with ascites. Patients 
who have ascites, particularly those with hyponatremia, bacterial 
infections, gastrointestinal bleeding, or severe sodium retention, are at 
high risk for renal failure, as are all patients hospitalized for acute 
decompensation of cirrhosis 
 
 Other than renal function tests, serum sodium, urine analysis(urine 
routine and 24 hr urinary protein) , renal ultrasonography, renal biopsy 
has to be done. 
 
 
 Renal biopsy is useful only in patients with protenuria/hematuria or 
both. It is contraindicated in severe coagulation abnormalities 
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 Patient should be evaluated for bacterial infections, iatrogenic causes. 
Patient medications should be  checked for diuretics , NSAIDS. These 
drugs should be discontinued.  
 
 
DIFFERENTIAL DIAGNOSIS OF RENAL FAILURE IN CIRRHOSIS 
 
 It includes pre- renal failure , intrinsic renal failure  and hepatorenal 
failure.  
 The patients should be evaluated both clinically and laboratory 
investigations to  arrive at a specific diagnosis.  Renal biopsy is not 
mandatory in patients with acute renal failure in cirrhotic patients.  
 Since the cirrhotic patients have sustained vasodilation, more prone for 
renal dysfunction which may be reversible if identified at early stage of 
the disease. 
 Presence of glomerulonephritis in the form of hypertension.purpura , 
arthralgia, Reynauds phenomenon would favour cryoglobulinemia 
associated with hepatitis C infection. 
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Rapid improvement with fluid challenge suggest pre-renal failure. If no 
improvement in renal parameters represents acute tubular necrosis or 
hepatorenal syndrome. Hepatorenal syndrome can improve with terlipressin 
or noradrenaline. 
 
 
Duplex ultrasonography is sensitive method for assessing the intrarenal 
hemodynamics with patients with cirrhosis and ascites 
 
 PROGNOSIS OF RENAL FAILURE IN CIRRHOSIS PATIENTS 
 
According to the literature, the prognosis in patients with cirrhosis and 
associated renal failure is poor. The survival rateis only 50% at 1 month and 
at the end of 6 months is 20%. The bad prognosis is probably due to 
combination of liver cell failure and renal dysfunction , also associated with 
complications (hyponatremia, thrombocytopenia, coagulopathy, infections) 
 
Survival rate depends on the type of renal failure and duration. With 
modern treatment modalities and early diagnosis can prevent the poor 
prognosis associated with renal failure. 
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Hepatorenalsyndrome  is associated with bad prognosis. Survival rate is 
poor with most of them has to undergo liver transplant for permanent 
treatment.  
HRS type 2 ( 6 months) has good prognosis compared to HRS type 1 
( 1 month). 
 
PREVENTION OF RENAL FAILURE IN CIRRHOSIS 
 
Early identification of reversible risk factors can reduce the high 
mortalilty. Two strategies are used  to prevent hepatorenal syndrome. 
 
First strategy is to perform liver transplantation in patients with cirrhosis 
and ascites with  high risk of developing HRS  based on MELD score before 
hepatorenal syndrome develops. 
 
Secondy strategy is to prevent development of renal failure by avoiding 
the precipitating factors( adequate management of bleeding and infection) 
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Spontaneous bacterial peritonitis is an important precipitating factor for 
hepatorenal / renal dysfunction in cirrhotic patients. SBP stimulates the 
production of tumour nerosis factor, pro inflammatory mediators leading 
activation of vasodilatory mechanism which further precipitates renal failure.  
 
Use of proper antibiotics(cefotaxime ) and albumin intravenously 
1.5g/kg followed by 1gm/kg after 48 hrs) can reduce the in hospital mortality.  
The beneficial effect of albumin is probably by preventinng circulatory 
failure and subsequent activation of  vasoconstriction mechanism during 
active infection 
 
OTHER RENAL ABNORMALITIES IN CIRRHOSIS 
 
• GLOMERULAR DISEASES  
In association with hepatitis B and C viruses and alcoholic liver 
disease 
 
• RENAL TUBULAR ACIDOSIS  
May occur in cirrhosis of different etiologies: primary biliary cirrhosis, 
autoimmune hepatitis and alcoholic cirrhosis 
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• DRUG INDUCED RENAL DYSFUNCTION  
    Especially with drugs like NSAIDs, aminoglycosides, diuretics or 
vasodilators 
 
 
 ACUTE TUBULAR NECROSIS 
              Due to volume depletion as seen in sepsis or hypovolemic shock( 
UGI Bleed) or due to nephrotoxic drugs 
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SEVERITY OF CIRRHOSIS CAN ASSESSED BY EITHER WITH 
MELD SCORE OR CHILD PUGH CLASSIFICATION 
  
 
                                   CHILD PUGH CLASSIFICATION 
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MELD SCORING 
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PROGNOSIS OF LIVER DISEASE 
 
Prognosis of liver disease depends on multiple factors  
 
Poor prognostic indicators 
• Marked ascites 
• Upper GI bleed 
• Advanced age 
• High daily alcohol consumption 
• High serum bilirubin 
• High alkaline phosphatase 
• Low serum albumin 
• Poor nutrition 
• Coagulopathy 
• Low serum sodium 
• Hepatic encephalopathy 
• Low platelet count 
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Scoring system to assess the prognosis  
1. Child pugh classification 
2. MELD Scoring system 
 
Child pugh scoring depends on – serum bilirubin, serum albumin, 
hepatic encephalopathy,ascites,prothrombin time. Previously used poor 
nutrition factor is replaced by prothrombin time. 
 
MELD score was developed initially for  the prognosis in patients 
undergoing TIPS surgery. It has been used for over all prognosis of liver 
disease and considered superior to child pugh score. 
 
It includes three variables- serum bilirubin, prothrombin time with INR , 
serum creatinine also includes the etiology of the liver disease. It is calculated 
based on the formula. 
 
MELD can be used a prognostic marker in patients with cirrhosis who 
developed renal failure. Predicts 3 month mortality. 
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MATERIALS AND METHODS 
  
 
 
 
All the inpatients admitted with chronic liver disease in thanjavur 
medical college were followed up prospectively from January 2016 to June 
2016 in Thanjavur medical college and hospital. 
 
Among those patients, irrespective of etiology  of the  cirrhosis( chronic 
liver disease) were followed up for a period of 2 weeks duration 
 
These patients were monitored for the elevated renal parameters in 2 
weeks period. So, the patients with increased renal parameters (serum 
creatinine) were included in the study 
 
All the patients were prospectively studied irrespective of age, sex and 
cause of chronic liver disease 
 
Data regarding demographic variables ( age, weight, height , BMI) were 
included for all the patients. 
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Clinical history including presenting complaints    (hematemesis, 
malena, jaundice, abdominal distension, abdominal pain, fever, altered 
sensorium)were noted accurately. 
 
Past history of alcoholism, alcoholic liver disease( duration, illness, 
course, previous similar complaints).Other major diseases ( SHT/DM/ 
CAD/CKD/PTB/EPILEPSY) were noted. History of native treatment and 
chronic drug intake were noted 
 
All the patients with known case of CKD were excluded from the study. 
 Complete general examination and gastrointestinal system examination 
done for all the patients including other system examination like 
cardiovascular, respiratory and central nervous system examination 
 
 
Clinical examination regarding the signs of liver cell failure were noted 
for all the patients 
 
Laboratory investigations included complete blood count, liver 
functions, renal function tests, prothrombin time, serum electrolytes were 
done. 
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Ultrasound abdomen for diagnosis( echotexture of liver), complications 
like portal hypertension, ascites  , splenomegaly ,to rule out chronic kidney 
disease( size of the kidneys) and to detect the structural pathology of kidneys 
and obstructive pathology of urinary tract. 
 
Renal function tests were sequentially  followed for 2 weeks duration( 
depends on individuals).Urine analysis in the form of urine routine and 24 hr 
urinary protein excretion to detect  significant proteinuria.Viral markers were 
done for the cause of cirrhosis in all the patients 
 
Ascitic fluid culture, chest x ray, urine culture and sensitivity, blood 
culture and sensitivity were done to find out the foci of infection. Cause of 
liver failure were identified by the history and laboratory investigations 
 
Precipitating factors were identified for the renal failure, factors 
affecting renal failure were analysed. Finally mortality of the patients with in 
2 weeks duration of inpatient hospitalisation has been assessed. 
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MELD score and child Pugh score were calculated for the prognostic 
signifance in all patients. Patients were followed up only for 2 weeks since 
many patinents either discharge/die with in this period. 
  
 
 Finally the outcome of the patient whether discharged/improved, 
worsened and died has been accounted. 
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MANAGEMENT STRATEGY  
 
1.  All patients are treated adequately with antibiotics  
2.   Avoided both nephrotoxic drugs and hepatotoxic drugs 
3.   Blood transfusion for massive UGI bleed 
4.   Fresh frozen plasma if there is documented/clinical coagulopathy 
5.   Platelet transfused as per need 
6.   Serum electrolytes were moniotored and corrected  
7.   Diuretics are stopped  if patient develops renal failure 
8.   Adequate iv fluids were given  
9. Hepatoprotective drugs were given 
10. Albumin if necessary is given with proper dosage 
11. Due to non- availability, terlipressin, midodrine were not given to the 
patients in the study group 
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OBSERVATION AND ANALYSIS 
 
Totally 40 patients with chronic liver disease along with renal 
dysfunction were enrolled in the study group from thanjavur medical college 
during the period of January 2016 to june 2016. 
 
The following observations were made  
 
AGE DISTRIBUTION 
 
Males- 38 
Females- 02 
 
 
  
38
2
SEX
Male Female
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AGE GROUP  
 
Patients were selected in all age groups.(above 13 yrs). 
 
 Age  distribution  is as follows in the study group. 
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ETIOLOGY OF LIVER FAILURE 
 
Liver failure caused by different etiologies were noted. All the patients 
irrespective of etiology were selected. 
Most of the patients in the study group are alcoholics 
 
 
 
 
 
Out of 40 patients 
Alcoholic related- 33 
NASH - 01 
Hepatitis B- 03 
Hepatitis C- 01 
Cryptogenic- 02 
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CAUSES/ PRECIPITATING FACTORS FOR RENAL FAILURE  
 
The most important precipitating factor for renal dysfunction is UGI 
Bleed in the study. 
3 patients with drug induced renal failure namely- 
diuretics,NSAIDS,entecavir. 
Other Infection related renal failure – UTI, Pneumonia, cellulitis 
 
Cause/precipitating factor No of patients Percentage (%) 
UGI BLEED 14 35% 
SBP 10 25% 
OTHER INFECTIONS 06 15% 
DRUGS 03 7.5% 
HRS TYPE 2 04 10% 
PARACENTESIS 01 2.5% 
UNKNOWN 02 5.0% 
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            Various precipitating factors for renal failure in the study group 
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Frequency of Admissions 
Number of patients with first time of admission- 15 
Number of patients with repeated admission - 02 
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LIVER FAILURE AND ASCITES 
 
 
As we know,Most of the decompensated liver disease present with 
ascites as their presenting complaint. Some patients may present with other 
forms like jaundice, UGI bleed, asymptomatic etc.. 
 It may depends on the stages of liver disease. 
 
 
Patients  presenting with Ascites- 34 
Patients without Ascites  - 06 
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HEPATIC ENCEPHALOPATHY 
 
 
Hepatic encephalopathy is important cause for mortality in patients with 
advanced liver disease. Early intervention is needed for the patients 
presenting with hepatic encephalopathy. 
 
Grades of hepatic encephalopathy 
 
 
Grade Detailed description 
I Mild confusion, euphoria, anxiety or depression, reversed sleep 
rhythm,slurred speech 
II Drowsiness , lethargy, gross deficits in the ability to perform mental tasks, relatively moderate confusion 
III Somnolent but arousable, severe confusion, inability to perform mental tasks 
IV Coma with or with out response to painful stimulus 
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Patients at the time of admission with hepatic encephalopathy were totally 12 
out of 40 patients 
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SERAL MONITORING OF  RENAL PARAMETERS IN STUDY GROUP   
S.NO NAME OF THE PATIENT 
DAY  1 (mg/dl) DAY 3(mg/dl) DAY 7(mg/dl) DAY 10(mg/dl) DAY 14(mg/dl) 
U C U C U C U C U C 
1 RAMU 84 3 65 2.8 60 1.2 45 1 - - 
2 PUNNIAMOORTHY 32 1.3 140 1.8 156 2 180 3.6 - - 
3 ARUL PRAKASH 43 2.1 48 1.5 2.8 1.1 - - 
  
4 YESURAJ 76 1.3 100 2 102 2.1 136 4.2 92 1.9 
5 SAUVIRAJ 43 1.5 42 1.9 36 1.2 28 1 - - 
6 SIVAKUMAR 64 2.8 96 3.8 36 1.6 30 1.2 - - 
7 NATARAJAN 112 5.8 135 4 140 4.2 120 3.8 - - 
8 MURUGESAN 102 2.1 120 1.8 42 0.9 - - - - 
9 SHEIKH ALI 45 1.2 68 1.8 60 1.6 76 3 110 4.6 
10 MEGANATHAN 115 3.5 134 4.2 130 4.8 140 4.2 80 3.6 
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S.NO NAME OF THE PATIENT 
DAY  1 (mg/dl) DAY 3(mg/dl) DAY 7(mg/dl) DAY 10(mg/dl) DAY 14(mg/dl) 
U C U C U C U C U C 
12 KALAISELVAN 60 2 70 1.9 40 0.6 30 0.8 30 0.5 
13 MURUGANANDHAM 87 2 110 2.5 100 2.2 89 2.1 42 1.2 
14 VENKATESH 42 1.4 69 2.3 42 1.1 40 1 - - 
15 DATCHANA MOORTHY 80 2.7 100 2.5 92 2.1 80 1.5 40 1.2 
16 NAINA MOHAMMED 70 1.5 72 1.4 60 1.2 30 0.8 - - 
17 MURUGIYAN 50 1.9 58 2.2 28 3.3 
  
- - 
18 AROKIASAMY 46 1.7 70 1.6 60 1.4 30 0.8 - - 
19 SHEK ALI 28 0.9 45 1.2 60 1.5 102 4.6 180 6.3 
20 THIRUVIYA SAYARAJ 80 1.5 48 1.2 22 0.7 28 0.7 -  
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S.NO NAME OF THE PATIENT 
DAY  1 (mg/dl) DAY 3(mg/dl) DAY 7(mg/dl) DAY 10(mg/dl) DAY 14(mg/dl) 
U C U C U C U C U C 
21 PALANI 108 2 115 1.5 100 1.2 64 1.4 43 1.1 
22 CHELLAPAN 105 2.3 85 1.5 90 1.6 85 1.2 36 1 
23 THIAYAGARAJAN 85 1.9 86 1.5 52 1.7 90 1.6 38 1.2 
24 SUSILA 55 1.9 95 2.6 86 1.9 50 1.8 40 1.2 
25 MURUGAN 28 1.1 50 1.5 85 2 100 3.4 115 4.1 
26 VIJAYA BHASKAR 70 1.4 50 1.3 88 2.5 65 1.9 42 0.8 
27 KALIYAPERUMAL 88 1.9 46 1.4 28 0.8 20 0.6 - - 
28 DHENADOSS 32 1.2 78 1.9 60 1.3 46 1 30 0.9 
29 VENKATESAN 78 2.6 96 3.2 86 3 78 2.6 46 1.4 
30 RAVICHADRAN 118 2.3 135 3 140 4 110 3.2 112 3.6 
31 RAJENDRAN 43 1.2 67 1.4 110 1.9 112 2.2 76 1.3 
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S.NO NAME OF THE PATIENT 
DAY  1 (mg/dl) DAY 3(mg/dl) DAY 7(mg/dl) DAY 10(mg/dl) DAY 14(mg/dl) 
U C U C U C U C U C 
32 SAMPATH 40 1.5 58 2.5 60 2.1 42 1.9 48 1.8 
33 MANIMAVAN 30 0.9 76 2 94 2.9 152 4.1 146 3.6 
34 SAVITHRI 34 1.2 42 1.7 38 1.2 28 0.9 - - 
35 BHASKAR 76 1.6 72 1.8 56 1.6 30 0.8 - - 
36 RAMADOSS 72 1.9 76 2.1 116 3.2 - - - - 
37 RAVI 76 1.3 86 1.9 92 2.1 56 1.1 40 0.8 
38 MUNIYANDI 50 2 56 1.5 38 2.1 42 1.9 46 2 
39 SUNDARAJ 63 2.1 67 1.6 62 1.5 42 1.4 30 0.8 
40 SAKTHIVEL 76 1.8 99 2.8 96 2.1 56 1.9 44 1.2 
 
U- Blood Urea 
C- Serum Creatinine  
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MORTALITY 
 
Mortality at the end of 2 weeks is 20 % i.e 8 out of 40 patients died 
There are various factors associated with death of the patients. 
 
 
 
 
 
Number of patients Alive – 32 
Number of died – 02 
 
Some of the patients were discharged after improvement. Some of them 
survived after the end of 2 weeks with or with out improvement in renal 
parameters. Finally 8 patients died with in two weeks due to various factors.  
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Analysis of clinical profile in dead patients is as follows 
 
We analysed the possible causes of renal failure in died patients as postulated  
Below 
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Causes of renal failure in dead patients 
 
 
 Cause of renal dysfunction  No of patients 
UGI bleed 04 
SBP 03 
Infection (cellulitis) 01 
 
 
 
ANALYSIS OF VARIOUS FACTORS IN DEAD PATIENTS 
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Parameters 
No of patients 
Hyponatremia ( <135 meq/l) 07 
Thrombocytopenia(<1 lakh/cumm) 06 
Serum creatinine(>3.2mg/dl) 08 
MELD Score(>30) 08 
Child C score 08 
 
 
Descriptive Statistics 
 N Min Max Mean S.D 
S.CR 40 1.50 6.30 2.7275 1.08675 
MELD 40 11 43 25.75 8.605 
 
 
N-  N.o of patients 
 
S.CR- serum creatinine 
 
S.D- Standard deviation 
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Percentage analysis  
 
Particulars No.of respondents (n=40) 
Percentage 
(100%) 
S.CR   
<3.2 30 75.0 
>3.2 10 25.0 
MELD   
<32 30 75.0 
>32 10 25.0 
Child   
A 4 10.0 
B 20 50.0 
C 16 40.0 
Outcome   
Improved 32 80.0 
Died 8 20.0 
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                                                    Chi –sqaure test 
 
                                                   T- test 
 
 n Mean  S.D t df Statistical inference  
MELD       
Improved 32 22.63 6.328 
-6.694 38 .000<0.01 Significant Died 8 38.25 3.454 
S.CR       
Improved 32 2.3719 .78380 
-5.457 38 .000<0.01 Significant Died 8 4.1500 .98416 
  
Df- degree of freedom 
 
Outcome Statistical 
inference Improved Died Total (n=32) (100%) (n=8) (100%) (n=40) (100%) 
S.CR        
<3.2 29 90.6% 1 12.5% 30 75.0% X2=20.833 
Df=1 
.000<0.05 
Significant  
>3.2 3 9.4% 7 87.5% 10 25.0% 
MELD        
<32 30 93.8% 0 .0% 30 75.0% X2=30.000 
Df=1 
.000<0.05 
Significant 
>32 2 6.3% 8 100.0% 10 25.0% 
Child        
A 4 12.5% 0 .0% 4 10.0% X2=15.000 
Df=2 
.001<0.05 
Significant 
B 20 62.5% 0 .0% 20 50.0% 
C 8 25.0% 8 100.0% 16 40.0% 
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                                                 DISCUSSION 
 
In this prospective study, totally 40 patients of cirrhosis with renal 
failure developed either initially at the time of admission or during the 
hospitalisation of 2 weeks duration are studied. 
 
Association of various factors, etiology/precipitating factors for renal 
failure and the final outcome of the patients during early hospitalisation was 
followed up. 
 
The mortality rate in our study is 20% with early diagnosis and adequate 
treatment in 2 weeks of follow up. 
 
As we know that patients with cirrhosis associated with renal failure 
have poor prognosis 
 
As stated by Chrysoulapippilli&evangeloscholongites , patients with 
advanced cirrhosis and renal failure are the high risk people who can be 
hardly be grouped to form precise instructions for diagnosis and treatment. 
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Acute kidney injury is portentous manifestation of circulatory failure on 
the patients with cirrhosis which has detriemental effect.Major etiology for 
development of liver disease is alcohol related. Etiology of liver disease has 
no relation with development of renal dysfunction.Ofcourse , development of 
renal dysfunction depends on various precipitating factors. 
 
According to the prospective study done by Andres cardenas & Pere 
Gines, renal failure is a frequent complication in patients with cirrhosis.In the 
study done by them, renal failure has occurred in about 11% of bleeding 
episodes in patients with cirrhosis. Out of those, 60% has irreversible renal 
failure.  
 
Independent risk factors for the development of renal failure in patients 
with UGI bleed are amount and intensity of bleed, hypovolemia/shock, late 
transfusion of blood and their products. 
 
Prognosis of patient depends on severity of cirrhosis, ascites at the 
admission, platelet count, hepatic encephalopathy at the time of admission, 
child pugh score, serum creatinine ( >2.1mg/dl), serum sodium value                           
(< 128meq/l) , MELD score. 
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High mortality in UGI Bleed is due to the combination effect of liver 
failure and renal failure along with persistent circulatory dysfunction as a 
consequence of cirrhosis with often precipitated by the bleeding. 
 
In our study , major cause/ precipitating factor for developing renal 
failure is UGI bleed. 14 ( 35%) of out 40 patients developed renal 
dysfunction due to UGI bleed which is significant number.Cirrhotic patients 
are more prone to develop various infections due to multiple pathological 
factors. 
 
Marilynn G Foreman, David M Mannino observed that cirrhotic 
patients are more likely to develop  both gram negative and gram positive 
sepsis with high mortaliy rate. 
It is due to  
• Acquired hypocomplementemia(decreased C3 levels) 
• Abnormal lymphocyte function 
• Reduction in reticuloendothelial system 
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All these factors leads to reduced clearance of bacteria from the portal 
circulation which consequently leads to both Gram Negative and Gram 
Positive sepsis. 
 
In OUR study, we detected both Gram Negative ( E.coli, klebsiella, 
psudeomonas) and Gram Positive( streptocococi, enterococcus)  from the 
ascitic fluid. 
 
SBP( spontaneous bacterial peritonitis) is an important precipitating 
factor for renal dysfunction in cirrhotic patients.It is due to arteriolar 
vasodilation,high cardiac output, hypotension, increased RAAS( renin 
angiotensin activating system), elevated AVP , increased endothelin and 
vasoactive cytokines leads to circulatory dysfunction. 
 
Hae Suk Cheong  observed that SBP occurs about 10%–25% of patients 
with liver cirrhosis and  ascites, with a mortality rate ranging from 20% to 
40% in his study. 
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Passage of bacteria from intestine to systemic circulation and then finally 
ascitic fluid is possible mechanism.Increased levels of IL- 6, TNF- alpha 
indicates severe infection. 
 
Renal impairment occurs in patients with increased levels of cytokines 
and deterioration of renal function is most important predictor for in hospital 
mortality. 
 
In our study, SBP is the second most important risk factor after UGI 
bleed. 25% of patients developed the renal failure due to spontaneous 
bacterial peritonitis in our study. 
 
According to the studies done by Richard & Didier lebree,  acute renal 
failure in cirrhosis mainly due to pre- renal ( GI bleed, renal and GI loses), 
sepsis, type 1 HRS. 
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True hypovolemia is important reversible factor.So, treatment directed 
against towards the cause of hypoperfusion/hypotension. Adequate fluid 
replacement is given to most of the pre- renal failure which is  reversible. 
 
We managed all the patients with adequate fluid replacement, blood and 
their products(platelets) at the appropriate time. 
 
The study done by Silvanofasolato, investigated the prevalence and 
clinical course of renal dysfunction which is induced by the bacterial infection 
in patients with cirrhosis and ascites. 
 
He found that prevalence of renal failure is higher in patients who 
develop complications like gastrointestinal infections, SBP, urinary tract 
infection. In his study, about 1/3 rd of cirrhotic patients with ascites will 
develop bacterial induced renal failure. 
 
In our study, 16 patients developed renal failure due to infection 
related( SBP, UTI, Pneumonia,cellulutis).so, 40% of the cirrhotic patients 
developed renal failure due to  infection in various forms. 
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Progressive form of renal failure with feature of HRS type 1 can be 
precipitated not only by SBP, but also by the GI tract infections( Acute 
gastroenteritis,biliary infections), UTI. The probability of infection related 
renal failure is related to MELD score, severity of infection, lack of resolution 
of infection. 
 
 According to hepatologist named L-Ruiz-del- arbo, large volume 
paracentesis can cause paracentesis induced circulatory dysfunction( PICD). 
Initially paracentesis ( >4L) can cause asymptomatic hypovolemia which 
further leads to renin system activation.PICD develops in  80% of patients 
who are not receiving plasma volume expanders ( like Albumin).There may 
be impaired renal function and rapid recurrence of development of ascites 
occurs. 
 
In our study , only 1 patient (2.5%) developed paracentesis induced 
renal dysfunction and reversed by albumin infusion and diuretic withdrawl. 
Incidence of paracentesis induced renal failure has been drastically reduced to 
modern treatment modalities. 
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There are many nephrotoxic drugs that can cause renal failure in 
cirrhosis patients. Aminoglycosides will increase the risk of occurrence of 
renal dysfunction in hospitalised patients which is supported by Fransceso 
savelenero. 
 
Drugs like diuretics,NSAIDS will cause renal failure by 
hemodynamically mediated. Close monitoring of renal function is essential in 
patients with ascites and SBP. With drawl of offending drug will reverse the 
damage. 
 
In our study , three patients developed renal failure due to drugs 
(NSAIDS, Diuretics,tenofivir) in cirrhotic patients. All the patients survived 
at the end of 2 weeks. 
 
A prospective study done by Fede G & D’ aminco –G, provides the 
evidence of increased risk of death in cirrhosis with renal failure. Finally , 
they have concluded renal failure increases the mortality with 7 fold rise with 
50% patients dying with in 1 month of duration. In our study, we assessed 
the outcome for 2 weeks( early hospitalisation). 
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Child pugh scoring has been widely used for severity of cirrhotic 
patients. According to modern literature, MELD score is used to assess the 
prognosis and is  better prognostic indicator which is more specific( liver 
specific) as it includes multiorgan ( liver and renal failure) 
 
Most of the patients with severe liver disease with MELD(Score>30) and 
child pugh C are associated with development of renal failure and also 
significant mortality ( 68%) as evidenced by the retrospective study of 
Dominique thalabut and Julien massard. Functional renal failure is major 
mechanism in cirrhosis patients. Outcome in those patients was poor. 
 
In our study, we found that total MELD score (>32 score) is associated 
with significant mortality  in all died patients with significant P value <0.02 
Use of pentoxylline can increase the renal blood flow. It can not reduce the 
short term prognosis, but can prevent long term complications in cirrhosis. 
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MELD scoring is used for good prognostic indicator /marker especially 
in patients with cirrhosis who developed renal failure.It predicts the mortality 
in 3 months period.MELD scoring depends on serum bilirubin value,serum 
creatinine, International normalised ratio and etiology of the liver disease. 
 
As supported by Teh-la huo, Jaw chingwv report which states that 
Ascites and Hepatic encephalopathy were significantly associated with 
increased MELD score at 3 months duration .MELD score has better 
prognostic significance than child pugh score. 
 
The occurrence of renal failure is a indicator of bad prognosis in 
cirrhosis irrespective of child’s classification.According to the retrospective 
study done by Yaghicsayegh R,  increased serum creatinine is a bad 
prognostic factor with significant decreased survival rate.So ,we made a 
correlation between the serum creatinine value in died and survived patients.  
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In our study, Maximum serum creatinine value in all died patients were  
more than 3.2mg/dl with bad prognostic index of significant  P <0.02 
compared with survived patients 
 
As evidenced by systemic analysis of PuneetaTandoon Guadalupe 
Garie – Tsao, renal dysfunction is the main prognostic indicator for cirrhotic 
patients with SBP followed by MELD score 
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CONCLUSION 
 
• Alcohol is the main etiological factor for chronic liver disease in the 
group 
• Patients should be watched for the development of renal failure in 
advanced liver disease 
• Identification of precipitating factors for renal failure is important 
• UGI bleed followed by SBP are the important precipitating factors/ 
events for the cause of renal failure 
• With adequate hydration, avoiding use of diuretics, prompt reversal of 
hypovolemia,early reversal of bleeding, use of adequate antibiotics, use 
of albumin , we encountered only 20% mortality rate during the early 
hospitalisation ( 2 weeks). 
• All the 8 patients who died present with high serum creatinine ( > 
3.2mg/dL), with child C score, high MELD score 
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• MELD score and Serum creatinine values are co- related with the 
mortality in cirrhotic  patients with renal failure 
• We found high MELD score(> 32) has significant association (p<0.02)  
even with the short term mortality in cirrhotic patients complicated 
with renal dysfunction 
• In dead patients with cirrhosis and renal failure, Serum creatinine(> 3.2 
mg/dl) has significant mortality co- relation ( P<0.02) 
• Child pugh score  also plays major role in mortality which significant 
(P<0.05) in died patients compared to survived patients 
• Even with out using terlipressin and midodrine, we encountered only 
20% mortality rate. 
• We conclude that early identification, intervention and treating the risk 
factors for renal failure will prevent / reduce the mortality in early 
hospitalisation( 2 weeks). 
• As many patients got either discharged/died during the study period, we 
could follow up patients only for 2 weeks duration.  
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PROFORMA 
NAME :                                                   I P NO-                      
AGE /SEX:                                              WARD/UNIT: 
ADDRESS:                                              HEIGHT/WEIGHT: 
                                                                BMI 
HISTORY OF PRESENTING ILLNESS 
jaundice 
fever 
abdominal pain  
abdominal distension 
decreased urine output 
hematemesis 
malena 
vomiting 
diarrhoea 
altered sensorium 
other symptoms 
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PAST HISTORY  
 DM / SHT/ CKD/ EPILEPSY/ HEPATITIS/CAD/TB/OTHERS 
Detailed history of Chronic Liver Disease - 
 
PERSONAL HISTORY 
alcoholic  ( duration)- 
Smoker- 
native medicine- 
h/o drug intake ( nephrotoxic)- 
 
VITAL SIGNS 
BP-                                                 SPO2- 
PULSE-                                           TEMP- 
 
GENERAL EXAMINATION 
consciousness - 
orientation - 
icterus - 
edema of legs - 
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SYSTEMIC EXAMINATION 
CVS - 
RS - 
ABDOMEN - 
CNS- 
 
INVESTIGATIONS 
Complete blood count - 
RBS - 
 
RENAL FUNCTION TEST 
DAY      0      2      5     10       15 
      
 
LFT( liver function test) 
urine routine ( casts)- 
Serum Electrolytes - 
PT and INR - 
24 hr urinary protein excretion- 
Ultrasound Abdomen - 
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Upper GI SCOPY - 
Ascitic fluid analysis 
sugar - 
protein - 
cytology- 
cell count - 
culture and sensitivity -  
chest x ray- 
urine culture & sensitivity- 
blood culture & sensitivity- 
viral markers- HEPA / HEP B/ HEP C/ HEP D 
 
CHILD SCORE -                               MELD SCORE- 
 
 
OUTCOME -DISCHARGED/ DIED/ RECOVERED/WORSEN  
  
 
CONSENT FORM 
Name of the participant: 
Documentation of the informed consent: 
 I have read the information in this form (or it has been read to me ). I was free 
to ask any questions and they have been answered. I am over 18 years of age 
and I am exercising my free power of choice, hereby give my consent to be 
included as a participant in the study of “A STUDY ON RENAL FAILURE 
PATIENTS IN CHRONIC LIVER DISEASE PATIENTS”. The nature and 
purpose of data is for research work. The procedure has been explained to me in 
detail in the language understandable to me by the investigator. It has been 
made clear to me that all personal details like name, place, religion, past history 
etc., will be kept strictly confidential. I permit the result obtained to be also used 
for academic purpose. 
 
Thanjavur 
Date: 
Signature of the patient: 
Investigator Certificate: 
  
I certify that all the elements including the nature, purpose and possible risks of 
the above study as described in this consent document have been fully explained 
to the subject.  
Signature of the investigator: 
Date: 
Name of the Investigator: 
 
 
  
 
PATIENT INFORMATION SHEET: 
 
You are being asked to take part in a research study entitled “A STUDY ON 
RENAL FAILURE PATIENTS IN CHRONIC LIVER DISEASE PATIENTS ”. 
You will not get any financial benefits from this study, but your participation 
may help future generations as it might help to reduce the mortality of renal 
failure in cirrhotic patients. 
Confidentiality is guaranteed. Your identity will not be revealed. You will have 
to sign a informed consent form. 
Your participation is completely voluntary. You may refuse to participate in the 
study or end your participation in the study at any time without penalty or loss 
of benefits to which you are otherwise entitled. You are free to ask any question 
during anytime of the study. We will try to answer any query that you may 
have. 
 
 
  
L A K
1  RAMU 30 M Alcoholic 10.4 2.2 30 sec 2.2 + 3 400 1.1 UGI BLEED S + N 35 C(12) SV 132 IMPROVED
2 PUNNIAMOORTHY 42 M Alcoholic 7.2 2 51 sec 4.63 + 3.6 210 0.21 UGI BLEED S + N 43 C (14) N V 111 DIED
3 ARUL PRAKASH 80 M NASH 3.6 2.2 16 sec 1.1 - 2.1 450 1.2 SBP S + N 19 B(9) S.V 125 IMPROVED
4 YESURAJ 34 M Alcoholic 9.6 3 11 sec 1.2 - 4.6 418 1.7 SBP N + N 30 B(9) S.V 142 IMPROVED
5 SAUVIRAJ 60 M Hep B 1.2 3.6 14 sec 1 - 1.9 312 2.9 DRUG N - N 13 A(5) N V 140 IMPROVED
6 SIVAKUMAR 45 M Alcoholic 12 4 15 sec 1.5 - 2.8 243 1.2 UTI S + N 30 B(8) S.V 139 IMPROVED
7 NATARAJAN 61 M Alcoholic 1.8 3.2 16 sec 1.2 - 4.8 418 1.7 HRS TYPE 2 S + N 24 B(7) S.V 135 IMPROVED
8 MURUGESAN 37 M Alcoholic 2.2 2.8 30 sec 2.8 + 2.1 200 0.07 UGI BLEED S + N 28 C(11) L.V 125 IMPROVED
9 SHEK ALI 44 M Alcoholic 11.8 2.5 36 sec 2.8 - 4.6 500 0.79 CELLULITIS S + N 41 C(12) L.V 130 DIED
10 MEGANATHAN 36 M Alcoholic 1.6 3.6 15 sec 1.2 - 3.5 260 2.4 HRS TYPE 2 N + N 22 A(6) NV 138 IMPROVED
11 SIVA 40 M Alcoholic 1 3.2 13.3 sec 1.1 - 1.5 410 1.2 UGI BLEED Ι - N 11 A(6) L.V 124 IMPROVED
12 KALAISELVAN 18 M Cryptogenetic 12.6 3.5 25 sec 2.3 + 2 900 1 UTI S + N 32 C(11) S.V 129 IMPROVED
13 MURUGANANDHAM 39 M Alcoholic 5.8 2.8 35 sec 2.8 + 2.5 600 0.08 UGI BLEED Ι - N 33 C(11) L.V 142 IMPROVED
14 VENKATESH 40 M Alcoholic 2.6 4 25 sec 2.18 - 2.3 512 2.6 UGI BLEED S - N 26 B(7) L.V 138 IMPROVED
15 DATCHANA MOORTHY 43 M Alcoholic 1.2 2.5 25 sec 1.8 - 2.7 400 0.78 SBP S + N 23 B(9) S.V 138 IMPROVED
16 NAINA MOHAMMED 42 M Alcoholic 1.8 3 50 Sec 2 - 1.5 480 1 UGI BLEED S + N 20 B(8) L.V 110 IMPROVED
17 MURUGIYAN 51 M Alcoholic 6.8 2.7 27 Sec 2.2 + 3.3 180 0.39 UGI BLEED N + N 34 C(13) NV 128 DIED
18 AROKIASAMY 36 M Alcoholic 1.2 3.6 13.5Sec 1.1 - 1.7 90 0.8 DRUG(Diuetic) S + N 13 A(6) L.V 142 IMPROVED
19 SHEK ALI 44 M Alcoholic 11.8 2 50  Sec 3.2 - 6.3 220 0.79 SBP N + N 42 C(12) S.V 133 DIED
20 THIRUVIYA SAGARAJ 37 M Alcoholic 2.6 3 14 Sec 1 - 1.5 300 1 SBP S + N 14 B(5) S.V 139 IMPROVED
21 PALANI 45 M Alcoholic 2.8 2.4 20Sec 1.6 - 2 338 0.51 UGI BLEED S + N 22 B(9) L.V 129 IMPROVED
S.B HES.NO NAME AGE SEX ETIOLOGY INR OUTCOMES.Na+S.A PT S.Cr U.P (mg) PLT (lakh) CAUSE OF RF
USG  ABDOMEN
MELD CHILD UGI SCOPY
L A K
S.B HES.NO NAME AGE SEX ETIOLOGY INR OUTCOMES.Na+S.A PT S.Cr U.P (mg) PLT (lakh) CAUSE OF RF
USG  ABDOMEN
MELD CHILD UGI SCOPY
22 CHELLAPAN 50 M Alcoholic 2 3 15Sec 1.2 - 2.3 608 0.84 PNEUMONIA S + N 19 B(8) L.V 132 IMPROVED
23 THIAYAGARAJAN 68 M HCV 1.2 3.3 19 Sec 1.5 - 1.9 70 2 ADD/AGE S + N 18 B(7) L.V 149 IMPROVED
24 SUSILA 36 F Alcoholic 3.8 3.2 25 Sec 1.9 - 2.6 110 1.6 UTI S + N 28 C(10) NV 142 IMPROVED
25 MURUGAN 27 M Alcoholic 4.2 2.2 48 Sec 3.2 - 4.1 240 0.76 SBP S + N 38 C(12) NV 130 DIED
26 VIJAYA BHASKAR 31 M Alcoholic 2.8 2.5 30 Sec 2.7 + 2.5 320 0.5 UGI BLEED S + N 30 C(12) L.V 120 IMPROVED
27 KALIYAPERUMAL 44 M Alcoholic 2.9 4.2 12 Sec 1 - 1.9 100 1.7 DRUG(NSAID) S + N 17 B(7) NV 133 IMPROVED
28 DHENADOSS 55 M
HBSAS
(HepB)
4.6 4 20Sec 1.6 - 1.8 80 1.2 UGI BLEED S - N 23 B(7) S.V 136 IMPROVED
29 VENKATESAN 42 M Alcoholic 4.2 3 23Sec 1.6 - 3.2 300 1.1 SBP(E-COLI) S + N 28 B(9) S.V 140 IMPROVED
30 RAVICHADRAN 50 M Alcoholic 2.2 2.6 40 Sec 2.8 + 4 144 1 UGI BLEED S - N 34 C(12) S.V 130 DIED
31 RAJENDRAN 50 M Alcoholic 10 2.4 19 Sec 1.5 + 2.2 200 1.2 SBP S + N 27 C(11) S.V 142 IMPROVED
32 SAMPATH 55 M Alcoholic 1 2  18 Sec 1.6 - 2.5 502 2 TYPE 2 HRS S + N 20 B(8) NV 140 IMPROVED
33 MANIMAVAN 48 M Alcoholic 5.8 1.7 30 Sec 2.6 + 4.1 320 1 SBP (NILGROWTH) S + N 37 C(13) NV 120 DIED
34 SAVITHRI 55 F Cryptogenetic 1.1 3.4 15 Sec 1.1 - 1.7 142 1.8
PARACENTESIS  
(>3L)
S + N 13 B(7) NV 144 IMPROVED
35 BHASKAR 38 M HCPB 4 3.2 20 Sec 1.9 - 1.8 159 1.2 UGI BLEED S + N 24 C(10) L.V 132 IMPROVED
36 RAMADOSS 42 M Alcoholic 7.2 3  48Sec 3 + 3.3 400 0.4 UGI BLEED S + N 37 C(13) L.V 128 DIED
37 RAVI 56 M Alcoholic 5.6 3.2 16 Sec 1.2 + 2.1 80 1.4
IDIOPATHIC
(UNKNOWN)
S + N 22 B(9) S.V 137 IMPROVED
38 MUNIYANDI 50 M Alcoholic 1.8 2 20 Sec 1.6 - 2 142 1.2 HRS TYPE 2 S + N 21 B(8) NV 140 IMPROVED
39 SUNDARAJ 55 M Alcoholic 0.9 3.5 23 Sec 1.5 - 2.1 400 0.9 SBP S + N 18 B(7) S.V 128 IMPROVED
40 SAKTHIVEL 48 M Alcoholic 2.1 3.6 18 Sec 1.2 - 2.8 366 1.4 UNKNOWN S + N 21 B(7) S.V 136 IMPROVED
KEY TO MASTER CHART 
M- MALES 
F - FEMALES 
S.B- SERUM BILIRUBIN 
ETIOLOGY- CAUSE OF LIVER FAILURE 
S.A – SERUM ASCITES 
PT- PROTHROMBIN TIME 
INR – INTERNATIONALISED NORMALISED RATIO 
HE- HEPATIC ENCEPHALOPATHY 
S.Cr- SERUMCREATININE ( mg/dl) 
UP- 24 HR URINARY PROTEIN EXCRECTION (mg/day) 
PLT- PLATELETS (Lakhs/cumm) 
L-LIVER SIZE 
A-ASCITES 
K- KIDNEY SIZE 
S- SHRUNKEN 
I- INCREASED 
N- NORMAL SIZE OF KIDNEYS/LIVER 
CHILD- CHILD PUGH SCORE ( A,B,C) 
MELD- MODEL FOR END STAGE DISEASE 
S.V- SMALL VARICES 
L.V – LARGE VARICES 
N V – NO VARICES 
S.NA – SERUM SODIUM (meq/l) 
